In its second largest deal to date, Hansoh Pharmaceutical Group has pledged up to US$1.316 B to Silence Therapeutics to collaborate and develop small interfering RNA (siRNA) molecules for three undisclosed targets. The partnership will leverage Silence’s mRNAi GOLD™ technology platform and provide Hansoh with rights to two targets in the China region and global rights to the third target. The deal comes just three days after Hansoh entered a collaboration with OliX Pharmaceuticals to develop and commercialise siRNA therapeutics in Greater China.